Treatment of patients with high risk localized prostate cancer: Results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE)

Journal of Urology

Volumn 173, Issue 5, 2005, Pages 1557-1561

  Meng, Maxwell V ^a,c   Elkin, Eric P ^a   Latini, David M ^a   DuChane, Janeen ^b   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Prostate; Prostatic neoplasms; Risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; AGED; ARTICLE; BODY MASS; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; EDUCATION; ETHNOLOGY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UROLOGY;

EID: 17244382914     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000154610.81916.81     Document Type: Article

References (20)

1. Jani, A. B. and Hellman, S.: Early prostate cancer: clinical decision-making. Lancet, 361: 1045, 2003
2. Grossfeld, G. D., Latini, D. M., Luback, D. P., Broering, J. M., Li, Y. P., Mehta, S. S. et al: Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology, 59: 560, 2002
3. Shipley, W. U., Thames, H. D., Sandler, H. M., Hanks, G. E., Zietman, A. L., Perez, C. A. et al: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA, 281: 1598, 1999
4. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Fondurulia, J., Chen, M. H., Kaplan, I. et al: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol, 17: 168, 1999
5. Tewari, A., Issa, M., El-Galley, R., Stricker, H., Peabody, J., Pow-Sang, J. et al: Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multiinstitutional study. Mol Urol, 5: 163, 2001
6. National Comprehensive Cancer Network: NCCN Practice Guidelines for Prostate Cancer. Version 3, 2002. Available at www.nccn.org/patient_gls/englis/_ prostate/index.htm. Accessed April 7, 2004
7. Moul, J. W., Connelly, R. R., Lubeck, D. P., Bauer, J. J., Sun, L., Flanders, S. C. et al: Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol, 166: 1322, 2001
8. Cooperberg, M. R., Broering, J. M., Litwin, M. S., Lubeck, D. P., Mehta, S. S., Henning, J. M. et al: The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol, 171: 1393, 2004
9. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A. et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280: 969, 1998
10. Kuczmarski, R. J., Ogden, C. L., Grummer-Strawn, L. M., Flegal, K. M., Guo, S. S., Wei, R. et al: CDC growth charts: United States. Adv Data, 8: 1, 2000
11. Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P. and Carroll, P. R.: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst, 95: 981, 2003
12. Carter, C. A., Donahue, T., Sun, L., Wu, H., McLeod, D. G., Amling, C. et al: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol, 21: 4001, 2003
13. Lerner, S. E., Blute, M. L. and Zincke, H.: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol, 154: 1447, 1995
14. van den Ouden, D., Hop, W. C. J. and Schröder, F. H.: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol, 160: 1392, 1998
15. Sylvester, J. E., Blasko, J. C., Grimm, P. D., Meier, R. and Malmgren, J. A.: Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys, 57: 944, 2003
16. Zagars, G. K., von Eschenbach, A. C. and Ayala, A. G.: Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer, 72: 1709, 1993
17. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. O. et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet, 360: 103, 2002
18. Manoharan, M., Bird, V. G., Kim, S. S., Civantos, F. and Soloway, M. S.: Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int, 92: 539, 2003
19. Konety, B. R., Eastham, J. A., Reuter, V. E., Scardino, P. T., Donat, S. M., Dalbagni, G. et al: Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol, 171: 709, 2004
20. Eastham, J. A., Kelly, W. K., Grossfeld, G. D., Small, E. J. and Cancer and Leukemia Group B: Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high risk localized disease. Urology, suppl., 62: 55, 2003